Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer
Authors
Yoon‐Koo Kang (ORCID: https://orcid.org/0000-0003-0783-6583)
Hyung‐Don Kim (ORCID: https://orcid.org/0000-0001-9959-0642)
Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer
Yoon‐Koo Kang, Hyung‐Don Kim, Min‐Hee Ryu, Hyungwoo Cho et al.
Citations
8 citations
Journal
Journal for ImmunoTherapy of Cancer
Topics
Gastric Cancer Management and Outcomes
Field-Weighted Citation Impact (FWCI)
12.15
article
Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer
Yoon‐Koo Kang, Hyung‐Don Kim, Min‐Hee Ryu, Hyungwoo Cho, Jong Seok Lee, Young Soo Park
article en
8 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal for ImmunoTherapy of CancerVol. 13(3)
Institutions
Ulsan College (KR), Asan Medical Center (KR), University of Ulsan (KR)
Funders
Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Daiichi Sankyo Europe